Description: BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders. The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany.
Home Page: www.biontech.de
BNTX Technical Analysis
An der Goldgrube 12
Mainz,
55131
Germany
Phone:
49 6131 9084 0
Officers
| Name | Title |
|---|---|
| Prof. Ugur Sahin M.D. | Co-Founder, CEO & Chair of the Management Board |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board |
| Prof. Christoph Hubert Huber M.D., Ph.D. | Co-Founder & Member of Supervisory Board |
| Mr. Jens H. Holstein | CFO & Member of Management Board |
| Dr. Sierk Poetting Ph.D. | MD, COO & Member of Management Board |
| Mr. Ryan Richardson | Chief Strategy Officer, MD & Member of Management Board |
| Mr. Sean Marett | Chief Bus. Officer, Chief Commercial Officer & Member of Management Board |
| Sylke Maas Ph.D. | VP of Investor Relations and Bus. Strategy |
| Dr. James Timothy Patrick Ryan Ph.D. | Sr. VP & Gen. Counsel |
| Michael Boehler | MD & Head of Global External Communications |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 9.8912 |
|---|---|
| Trailing PE: | 3.5365 |
| Price-to-Book MRQ: | 2.3324 |
| Price-to-Sales TTM: | 2.3797 |
| IPO Date: | 2019-10-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 4000 |